New Studies on the Circulatory Effects of Ergot Compounds with Implications to Migraine

  • B. Berde


Ergot alkaloids have come to assume a pivotal position in migraine therapy. Not only does this group include the most potent drugs for the relief of the acute attack, but it also provides the most effective prophylactic drugs available.


Vascular Resistance Ergot Alkaloid Blocking Activity Inversion Point Noradrenaline Content 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aellig, W. H. (1967). Periphere Kreislaufwirkungen von Ergotamin, Dihydroergotamin und 1-Methyl-ergotamin an der innervierten, perfundierten Hinterextremität des Hundes. Helv. physiol. pharmacol. Acta, 25, 374.Google Scholar
  2. Aellig, W. H. and Berde, B. (1969). Studies of the effect of natural and synthetic polypeptide type ergot compounds on a peripheral vascular bed. Brit. J. Pharmacol. 36, 561.CrossRefGoogle Scholar
  3. Cerletti, A. and Berde, B. (1969). New approaches in the development of compounds from ergot with potential therapeutic use in migraine. In Background to Migraine. London: William Heinemann Medical Books.Google Scholar
  4. Konzett, H. and Rothlin, E. (1953). Investigations on the hypotensive effect of the hydrogenated ergot alkaloids. Brit. J. Pharmacol. Chemother. 8, 201.CrossRefGoogle Scholar
  5. Pacha, W. and Salzmann, R. (1970). Inhibition of the re-uptake of neuronally liberated noradrenaline and α-adrenergic blocking action of some ergot alkaloids. Brit. J. Pharmacol. 38, 439.Google Scholar
  6. Rothlin, E. (1946/47). The pharmacology of the natural and dihydrogenated alkaloids of ergot. Bull. Schweiz. Akad. med. Wiss. 2, 249.Google Scholar
  7. Salzmann, R. and Pacha, W. (1968). Vergleichende Untersuchungen über die Beeinflussung adrenerger Reaktionen durch Ergotamin und Dihydroergotamin an verschiedenen Versuchsmodellen. Helv. physiol. pharmacol. Acta, 26, 246.Google Scholar
  8. Salzmann, R., Pacha, W. and Taeschler, M. et al. (1968). The effect of ergotamine on humoral and neuronal actions in the nictitating membrane and the spleen of the cat. Naunyn-Schmiedebergs Arch. Pharm. exp. Path. 261, 360.CrossRefGoogle Scholar
  9. Salzmann, R., Pacha, W. and Weidmann, H. (1967). Der Einfluss von Ergotamin auf humorale und neuronale Wirkungen an der Nickhaut und an der Milz der Katze. Helv. physiol. pharmacol. Acta, 25, 433.Google Scholar
  10. Thoenen, H., Hürlimann, A. and Haefely, W. (1963). The effect of post-ganglionic sympathetic Stimulation on the isolated, perfused spleen of the cat. Helv. physiol. pharmacol. Acta, 21, 17.Google Scholar
  11. Thoenen, H., Hürlimann, A. and Haefely, W. (1964). Dual site of action of phenyoxybenzamine in the cat’s spleen: blockade of α-adrenergic receptors and inhibition of re-uptake of neurally released norepinephrine. Experientia (Basel), 20, 272.CrossRefGoogle Scholar
  12. Udenfriend, S. (1964). Fluorescence Assay in Biology and Medicine, page 158. New York/London, Academic Press.Google Scholar

Copyright information

© Springer Science+Business Media New York 1971

Authors and Affiliations

  • B. Berde

There are no affiliations available

Personalised recommendations